Biotech and Pharmaceuticals Biotechnology

  • Step away from biotechs, let dust settle: Pro

    David Seaburg, Cowen & Company, Jerry Castellini, CastleArk Management, discuss the biotech sector as the IBB heads into bear market territory.

  • IBB enters bear territory

    The IBB, biotech ETF has officially entered bear market territory, and has fallen below the level where it was after the flash crash. CNBC's Brian Sullivan and Melissa Lee discuss.

  • Could Spark cure blindness?

    CNBC's Meg Tirrell looks at events in biotech that could help the sector out of it's recent struggles. The Fast Money traders discuss the trade.

  • Turing CEO: Will lower drug price ... eventually

    NBC News' Andrea Mitchell reports Turing Pharmaceuticals CEO Martin Shkreli will lower the price of Daraprim, which was raised 5,000 percent over the weekend. He says it will happen in the next few weeks.

  • A huge overnight price increase for an important tuberculosis drug has been rescinded after a public outcry, the NYT reports.

  • Neurocrine crushes the IBB

    Kevin Gorman, Ph. D., President, CEO, Neurocrine Biosciences, explains how his company is up 144 percent so far this year.

  • Can biofuels replace oil in the future?

    Peder Holk Nielsen, CEO of Novozymes, says it has become tougher for renewables and biofuels to compete with fossil fuels.

  • Biotech pharmaceuticals

    Short sellers are continuing to target biotechnology stocks as one of the frothiest sectors in US equities staggers after a bruising August.

  • First biosimilar hits US

    CNBC's Meg Tirrell reports on what could be a new era for U.S. medicine.

  • Health care mergers and acquisitions set to continue

    Fred Hassan, managing director of healthcare and consumer for Warburg Pincus, says we will see more M&A in the health care sector.

  • Biotechs rally back

    Discussing which biotechs may have been oversold in the selloff, with Michael Yee, RBC Capital biotech analyst.

  • Time for biotech to bounce back?

    David Seaburg, Cowen & Company, and Craig Johnson, Piper Jaffray & Co, discuss biotech, a formerly hot sector that's down more than 7 percent in a month.

  • Bass's biotech beef

    One biotech stock could see massive moves later this month, thanks to the meddling of hedge fund heavy hitter, Kyle Bass. CNBC's Meg Tirrell reports the latest.

  • Has biotech peaked?

    The ETF that tracks biotechs, BBH, is up nearly 16 percent to date. Dominic Chu looks at whether there's still more room to run.

  • CSL employees.

    CSL has warned of a "biotech bubble" amid a frenzy of mergers and acquisition activity across the healthcare sector, the Financial Times reports.

  • IBB claws its way back

    The Nasdaq biotech ETF IBB is coming back after tumbling more than 4 percent toward the end of last week. Is now the time to buy, with Eric Schmidt, Cowen & Co., and John Sonnier, with William Blair & Co.

  • Teva to acquire Allergan for $40B

    A major deal in the pharma space, Teva says it will buy Allergan's generics business in a deal worth a little over 40 billion dollars. CNBC's Meg Tirrell reports the details.

  • First Malaria vaccine

    Insight on malaria prevention, with Monceff Slaoui, GlaxoSmithKline, who is committed to the social responsibility of saving lives.

  • Biotech research

    Biotech is going to break out, RBC Capital Markets' Michael Yee said. There are the names on his buy list.

  • This will change the face of human health: Pro

    CNBC's Meg Tirrell dives into how J&J plans to tackle autoimmune disease and why health care professionals say the microbiome "is going to change the face of human health."